This podcast is a report on the Advance-HTN trial, a multicenter, double-blind, randomized, placebo-controlled study investigating the efficacy and safety of lorundrostat, an aldosterone synthase inhibitor, in patients with uncontrolled and treatment-resistant hypertension. The study found that lorundrostat was associated with greater reductions in 24-hour average blood pressure compared to a placebo over a 12-week period. While hyperkalemia and decreased kidney function were observed more often with lorundrostat, the overall safety profile appeared acceptable. This research highlights the potential of aldosterone dysregulation as a contributor to resistant hypertension and suggests lorundrostat may be a viable treatment option, particularly in populations disproportionately affected by this condition.